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Abstract 
 
Introduction: Newborn screening (NBS) is an important public health measure aimed at early 
identification and management of affected newborns. Sickle Cell Disease (SCD), with an 
estimated 5,200 live births every year, is a major public health problem in India. Pre- 
symptomatic diagnosis, institution of pneumococcal prophylaxis and provision of comprehensive 
care offer the possibility of prevention of complications and improving outcome of SCD. 
In India, SCD is highly prevalent among autochthonous ethnic groups called scheduled 
tribes. These communities also have a high prevalence of extreme socio-economic disadvantage. 
The population of scheduled tribes in the western state of Gujarat exceeds 14 million individuals. 
Since 2008 NBS for SCD has been piloted in Valsad and nearby areas. NBS is currently being 
expanded to other tribal districts in the state. Evaluation of the NBS program is essential for 
guiding the implementation of NBS in Gujarat and elsewhere. 
Objectives: To evaluate the pre-analytical, analytical, post-analytical, and organizational 
aspects of the pilot NBS Program for SCD in Valsad, Gujarat, India. 
Methods: Using a standardized Performance Evaluation and Assessment Scheme (PEAS) for 
NBS modified for developing countries we performed systematic evaluation of the pre- 
analytical, analytical, post-analytical, and organizational aspects of the pilot NBS Program for 
SCD in Valsad. 
Results: Since the inception of NBS in 2008 more than 3500 newborns have been screened using 
High Pressure Liquid Chromatography and iso-electric focusing with confirmation by molecular 
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methods. Individuals identified with SCD receive comprehensive care and families of those with 
sickle cell trait receive genetic counseling. Using modified PEAS methodology the pre- 
analytical, analytical and post analytical aspects of the NBS program received a score of 37/46 
meeting 80.4% of standards. The organizational domains received a score of 32/34 meeting 94% 
of standards. 
Public Health Implications: There has been a serious lack of information on the feasibility of 
newborn screening and comprehensive care for hemoglobinopathies in a developing country. 
These data demonstrate the feasibility of implementing NBS for SCD among communities facing 
extreme social disadvantage in a developing country. They provide the framework for 
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Newborn screening is recognized internationally as an essential, preventive public health 
program for early identification of disorders in newborns that can affect their long term health. 
Early detection, diagnosis, and treatment of certain genetic, metabolic, or infectious congenital 
disorders can lead to significant reductions of death, disease, and associated disabilities.(1) 
Newborn screening is now present in most countries in Europe, Australia, New Zealand, the 
Philippines and other countries around the world but the diseases screened and the methods used 
vary from country to country. With the completion of the Human Genome project, the expansion 
of genetic knowledge and technology into the public health arena has risen and has presented 
opportunities for understanding and promoting health, lowering mortality and morbidity rates, 
and preventing diseases.(2) 
Initiation of newborn screening in developing countries has been slow because of a 
variety of factors. Developing countries face challenges related to poor economies, unstable 
governments, unique cultures, geographic extremes, and different public health priorities.(3) The 
various languages and dialects present in developing countries also pose a difficulty since it can 
cause communication problems. This impedes researchers and experts in newborn screening 
from developed programs from communicating and advising individuals in countries with 
developing programs.(3) Regardless, newborn screening is becoming a priority in many 
developing countries around the world. 
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Historically, the initiative in creating a newborn screening program has come from 
individuals and groups that are interested and concerned about improving the lives of newborns 
and the well-being of families. However, in order for a successful and sustainable newborn 
screening program, the newborn screening system needs to intersect with government public 
health activities. Success in developing and institutionalizing newborn screening has resulted 
from the continued efforts of dedicated leaders willing to gain proficiency in newborn screening 
medical and laboratory science to overcome political, cultural, and economic challenges.(3) 
While over fifty countries around the world have implemented some sort of genetic 
screening system, India, with the second largest population in the world, still has no national 
newborn screening program. A few private laboratories offer screening services but those 
services are only accessible to those that can afford the costs which the majority of the 
population in a country like India cannot. A few states have taken the initiative to establish pilot 
screening programs but until the national government takes a stance and invests in a screening 




1.1 PUBLIC HEALTH RELEVANCE 
 
 
The Centers for Disease Control and Prevention (CDC) established the Office of Public Health 
Genomics aimed to integrate genomics into public health research, policy and programs, which 
could improve interventions designed to prevent and control the country’s leading chronic, 
infections, environmental and occupational diseases.(1) Newborn screening, an example of a 
program in the field of public health genomics, in the United States has been extremely 
successful,  preventing  thousands  of  premature  illnesses  and  deaths  per  year.  Many  of  the 
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conditions identified through newborn screening are metabolic disorders, once identified these 
disorders can be treated before severe symptoms such as mental retardation and developmental 
delays appear and become permanent. 
Approximately one out of every 1,500 babies will be born with one of the disorders 
detectable through newborn screening.(2) Less than ten percent of babies born in the US 
currently get comprehensive screening for all metabolic, endocrine and hematological disorders 
already detectable through existing routine newborn screening programs and six babies are born 
every day in the United States alone that have disorders detectable through newborn screening 
but go undetected because they are not screened.(1, 2) Conditions identified through newborn 
screening can lead to disability or death without proper intervention and management. Screening 
programs collect more blood samples than are necessary to complete screening tests in most 
infants. If given permission the extra samples can also be used for the development of new 
methods and tests that can help identify even more conditions. 
In order to include a certain condition in a newborn screening program, there are certain 
prerequisites that should be met prior, in order to achieve optimal results: 
1.1.1 in regard to the condition, it should represent a relevant public health 
problem, with natural history well-known and the diagnosis should be 
possible in a pre-symptomatic stage (4) 
1.1.2 in regard to the test, it should be safe, reliable, inexpensive, cost-
effective, with a good specificity and sensibility, represent or cause no 
physical or psychological harm, and it should allow to quality control 
measures (4) 
1.1.3 in regard to the management, it should be effective, and be associated 




For conditions for which not all criteria are met, for example, the existence  of  an 
effective management that changes the natural course of the condition, the inclusion of the 
condition in a screening program is questionable.(4) 
Newborn screening provides a quick and inexpensive way to identify numerous 
conditions that can be treated effectively from birth. These conditions if left untreated can cause 
problems and symptoms that will require lifelong care and management. The quality of life is 
drastically higher for affected individuals that are treated from birth compared to individuals that 




1.2 INDIA: GENERAL INFORMATION 
 
 
India has a universal health care system run by the local (state or territorial) governments. 
Government hospitals provide treatment at taxpayer expense. The Constitution charges every 
state with “raise of levels of nutrition and the standard living of its people and the improvement 
of public health as among its primary duties.”(5) Most essential drugs are offered free of charge 
in these hospitals.(1) However, the government sector is understaffed and under-financed. The 
very poor standards at these state-run hospital force many people to visit private medical 
practitioners or seek complex treatment and health services outside the country. 
The National Health Policy approved by the Indian parliament in 1983, and updated in 
2002 failed to mention the importance of implementing a genetic screening system in India.(6) 
Whereas, 52 countries across the world (using Dried Blood Spot as a sample) are currently 
implementing some form of newborn screening mandatory at the national level.(3) Neonates are 
not screened in India partly because the health policies have typically targeted mortality and 
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infectious morbidities but not disabilities. Their health policies have been successful in reducing 
infant mortality rates, but the net effect of these gains has been offset by an increase in disability, 





1.2.1 Current State of Affairs 
 
 
While the federal government of India has yet to implement a mandatory screening program for 
newborn babies, some state governments have already carried matters into their hands and have 
started implementing a mandatory NBS program within their state.(3) For the past two years the 
state government of Goa in western India screens every newborn in their health care facilities for 
50 disorders.(8) Few laboratories and hospitals in India are only offering this as an option to the 
parents but with growing awareness of the importance of NBS, the parents are now voluntarily 
opting for comprehensive genetic screening from private laboratories and paying additional 
charges for NBS service.(7) Influences from developed countries and a sharp increase in Internet 
usage in the Indian population are mainly responsible for the increase in awareness of NBS in 
India. There is one lab in India that offers screening of more than 100 disorders, primarily by 
urine. Urine sampling is not the accepted NBS paradigm worldwide, despite the higher accuracy 
and sensitivity of the procedure.(8) The premium cost is one of the reasons it is not available to 
public at large through the national government establishments. The sample accepted worldwide 
for Newborn Screening remains Dried Blood Spot (DBS) and after indication of a disorder, the 
urine sample is recalled for confirmation. (1, 3, 8) The obvious negative for this procedure is loss 
of time for the newborn at risk. Mostly the NBS program in the world uses DBS, though the 
paradigm is slated for a change as the science evolves. 
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One of the prerequisites for a screening program is the availability of epidemiological 
data regarding disease burden. However, genetics being a combination of high end research plus 
information technology requires an ultramodern facility as well as a network of specialized 
clinicians to make parents aware and also treat the positive, implementing such an expensive and 
inclusive screening has been overlooked and delayed in India. 
 
 
1.2.2 Pilot Studies for Newborn Screening 
 
 
It may not be viable economically and ethically to screen for a complete range of disorders for 
which diagnostics modalities are available. Specific criteria that serve as a template to decide 
what disorders to include in the screening at a national platform are: (1) biochemically well 
identified disorder; (2) known incidence in the population; (3) disorder associated with 
significant morbidity and mortality; (4) effective treatment available; (5) period before which 
intervention improves outcome; and (6) availability of an ethical, safe, simple and robust 
screening test. The developed countries have prioritized the diseases according to the incidence. 
For most developed countries, initial targets for screening were phenylketonuria and congenital 
hypothyroidism, but now have expanded to other genetic disorders like congenital adrenal 
hyperplasia (CAH) , cystic fibrosis, galactosemia, G6PD deficiency, biotinidase deficiency, 
hemoglobinopathies e.g. Sickle Cell Disease (SCD), and non-genetic targets such as hearing and 
intrauterine infections, especially toxoplasmosis.(1, 3) 
The state of Gujarat in India is the first state to implement a program for screening and 
treatment of hemoglobinopathies. Hemoglobinopathies including Thalassemia with an estimated 
10,000 live births each year and sickle cell disease (SCD) with an estimated 5,200 live births 
each year is a major public health crisis in India. The objective for this newborn screening 
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program is to combine the establishment of high laboratory screening methods, strategies for 
follow-up, standardized clinical care, information technology for tracking patient care and socio- 
behavioral studies to determine the feasibility, efficacy and acceptability of a newborn screening 













Newborn screening consists of 6 components: education, screening, follow-up, diagnosis, 
management and evaluation. It is commonly a system that functions within local geographic, 
economic, and political constraints, and seeks to integrate sample collection, laboratory analysis, 
follow-up diagnosis and treatment.(9) The Maternal and Child Health Bureau within the United 
States Health Resources and Services Administration provided funding to develop  realistic 
quality assessment indicators for assessing and improving the quality of NBS systems.(10) This 
resulted in the creation of an evaluation assessment scheme entitled the Performance Evaluation 
Assessment Scheme (PEAS). PEAS is a comprehensive listing of quality indicators for system 
self-assessment. The U.S. PEAS emphasized improved operation of screening and follow-up 
through a system of self-evaluation and quality assurance.(3, 11)The development project 
included an oversight committee of knowledgeable individuals experienced in working with 
NBS systems (including consumers) to: (a) better define the goals of the project; (b) outline the 
activities necessary to complete the goals and the project; (c) review and develop working group 
charges and challenges; (d) develop a timeline for project completion; (e) review and develop a 
project evaluation plan; and (f) provide ongoing project oversight.(3, 11) The evaluation 
assessment is divided into four stages: pre-analytical (education and screening), analytical 
(laboratory   testing),   post-analytical   (reporting,   short-term   follow-up/tracking,   diagnosis, 
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treatment/management, ancillary services, and outcome evaluation), and organizational. (10) 













The aim of this project was to determine the steps needed to evaluate the pre-analytical, 
analytical, post-analytical, & organizational stages of a pilot Newborn Screening Program for 
SCD and other hemoglobinopathies in the tribal districts of Gujarat and identify gaps and 














The original PEAS model was developed in the United States which has a more complex and 
comprehensive newborn screening program. Previously, the PEAS model was used to evaluate 
the Philippine newborn screening program.(11) The framework of evaluating the Philippine 
newborn screening program was used as a model when creating measurable indicators for 
inclusion in the Gujarat PEAS. Collaborators from the U.S., the Valsad Raktadan Kendra (site of 
the newborn screening program) and the Indian Council of Medical Research in Mumbai, India 
were involved in the PEAS development process. Both the U.S. and Philippine process were 
reviewed along with the indicators developed. If appropriate, a particular indicator was then 
added to the Gujarat PEAS evaluation. Due to the small infrastructure of the program in Gujarat, 
many of the evaluation indicators were modified to meet the modest demands of the local 
system. These modified indicators where then compiled into a list to create the final PEAS 
document. These modified standards were distributed to the screening facility and a  team 
member and director of the screening program reviewed the screening facility in accordance with 
these guidelines.(11) The individuals reviewed records, action plans and other relevant 
information, discussed program issues and goals, solutions and current state of progress in 
program implementation.(10, 11) 
The PEAS scoring system, adopted from the Philippine evaluation, for the newborn 
screening facility, Figure 1, was qualitative with eight qualitative areas of interest assessing 
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overall performance.(10, 11) Each of these areas were characterized with one or more indicators 
for which the response could be ‘yes,’ ‘no,’ or ‘maybe.’ The scoring for the newborn screening 
program administration included quantitative evaluation of five groups of indicators covering 
operational structure, plan of action, systems in place, health promotion plan and a contingency 
plan as shown in Figure 2.(10, 11) For each area of interest, there were several indicators and 
each could be assessed as yes (in place and monitored), no (not in place), or ‘in progress.’ Points 
were given for yes = 1 and no = 0 and items in progress were not given points.(10, 11) Results of 
PEAS scores were summarized and overall performance for the pilot program was assessed. 













Figures 1 and 2 show the results of the PEAS scoring. Figure 1 represents the evaluation of the 
pre-analytical, analytical and post-analytical stages. Of the indicators assessed in this evaluation, 
the pilot newborn screening met 37/46 (80.4%) of standards. Figure 2 represents the evaluation 
of the organizational component of the newborn screening program. For this portion of the 
evaluation, 32/34 (94%) of standards were met. 
Initiation of newborn screening in developing countries has been slow because of a 
variety of factors. Developing countries face challenges related to poor economies, unstable 
governments, unique cultures, geographic extremes, and different public health priorities.(3) The 
various languages and dialects present in developing countries also pose a difficulty since it can 
cause communication problems. This impedes researchers and experts in newborn screening 
from developed programs from communicating and advising individuals in countries with 
developing programs. Regardless, newborn screening is becoming a priority in many developing 
countries around the world. 
The state government of Goa introduced a universal newborn screening program for a 
period of four years beginning in 2008. This program was the first to screen every newborn in 
the state for 50+ genetic conditions in India.(8) The states of Chhattisgarh, Andhra Pradesh, and 
Gujarat have also all implemented pilot newborn screenings for various conditions, however,  no 
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formal evaluation have been performed to assess and identify gaps, solutions and areas of 
improvement.(7, 8, 12-15) 
The comprehensive newborn screening system performance evaluation scheme (PEAS) 
published by Therrell et al (10) has been successfully adapted to evaluate newborn screening 
programs in the developing world.(11) Using these standards we present the results of our self- 
assessment of newborn screening system and have identified areas of strengths as well as barriers 
that have to be overcome for future implementation of newborn screening programs in India. 
This evaluation serves as a baseline to identify gaps in the program that need to be addressed as 
the program becomes integrated into the state health system. As a result of the assessment a 
formalized action plan clearly indicating the targets and goals of the newborn screening program 
was created and a mechanism for routine monitoring and continual review of program 

























The information gained from this evaluation provides information that is essential to improve the 
quality of the newborn screening program. As newborn screening programs are developed and 
expanded it is important that there are standards to follow and PEAS serves as a quality self- 
assessment tool. There is a lack of information on the feasibility of newborn screening and 
comprehensive care for hemoglobinopathies in a developing country. Using PEAS as a standard, 
multiple evaluations, spanning a number of years, will provide important feedback to the 
advancement of the newborn screening program in Gujarat. This information will also be 
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